Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the relapse prevention efficacy of lurasidone compared with quetiapine XR (QXR) in adults patients with schizophrenia. METHOD: This double-blind study evaluated the relapse prevention efficacy of 12 months of flexible-dose treatment with lurasidone (40-160 mg/day) compared with QXR (200-800 mg/day), in outpatients with an acute exacerbation of chronic schizophrenia who had recently completed a 6-week placebo-controlled trial of treatment with either lurasidone or QXR. The primary endpoint, time-to-relapse, was analyzed using a Cox proportional hazards model in this noninferiority trial. RESULTS: The Kaplan-Meier estimate of the probability of relapse over 12 months was 23.7% for subjects receiving lurasidone vs. 33.6% for QXR. The hazard ratio [95% CI] for probability of relapse was 0.728 [0.410, 1.295] (log-rank p=0.280). Since the upper limit of the hazard ratio (1.295) was smaller than the prespecified noninferiority margin (1.93), noninferiority of lurasidone compared with QXR was demonstrated in this study. The probability of hospitalization at 12 months was lower for the lurasidone group compared with the QXR group (9.8% vs. 23.1%; log-rank p=0.049). A significantly higher proportion of lurasidone subjects achieved remission at study endpoint compared with the QXR group (61.9% vs. 46.3%; p=0.043). Discontinuation rates due to AEs were similar for lurasidone and QXR (7% vs. 5%). Treatment with lurasidone was not associated with clinically significant changes in weight or metabolic parameters. CONCLUSIONS: Twelve months of treatment with lurasidone met noninferiority criteria, and was associated with higher rates of remission, and reduced risk of hospitalization compared with QXR. No clinically significant effects on weight or metabolic parameters were observed during maintenance treatment with lurasidone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio, G., Elbourne, D. R., Altman, D. G., Pocock, S. J., Evans, S. J. W., & CONSORT Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.10.1152 · Cited by 1,153
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931 · cited 2×
“In a meta-analysis of 65 placebo-controlled trials (Leucht et al., 2012), antipsychotic agents were found to significantly reduce relapse rates at 12 months when compared with placebo (antipsychotics 27% vs.”
Twenty-five year mortality of a community cohort with schizophrenia
Brown, S., Kim, M., Mitchell, C., & Inskip, H. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.067512 · Cited by 601 · cited 1×
“With evidence suggesting that cardiovascular mortality risk in schizophrenia may have increased since the introduction of atypical antipsychotics (Saha et al., 2007; Weinmann et al., 2009; Brown et al., 2010), there is little doubt that additional metabolically neutral antipsychotic treatment options are needed, in ad…”
Influence of antipsychotics on mortality in schizophrenia: systematic review
Weinmann, S., Read, J., & Aderhold, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.018 · Cited by 224 · cited 1×
“With evidence suggesting that cardiovascular mortality risk in schizophrenia may have increased since the introduction of atypical antipsychotics (Saha et al., 2007; Weinmann et al., 2009; Brown et al., 2010), there is little doubt that additional metabolically neutral antipsychotic treatment options are needed, in ad…”
Cited by
Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Sarma, K., Xu, J., & Calabrese, J. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070985 · Cited by 293
Self-citationLeucht, S., Schneider‐Thoma, J., Burschinski, A., Peter, N., Wang, D., Dong, S., Huhn, M., Nikolakopoulou, A., Salanti, G., & Davis, J. M. (2023) · World Psychiatry · doi:10.1002/wps.21089 · Cited by 78
Suppes, T., Kroger, H., Pikalov, A., & Loebel, A. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.03.012 · Cited by 65
Self-citationCalabrese, J. R., Pikalov, A., Streicher, C., Cucchiaro, J., Mao, Y., & Loebel, A. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.06.013 · Cited by 55
Self-citationCorrell, C. U., Cucchiaro, J., Silva, R., Hsu, J., Pikalov, A., & Loebel, A. (2016) · CNS Spectrums · doi:10.1017/s1092852915000917 · Cited by 48
Self-citation
Metadata
- Authors
- Loebel, A., Cucchiaro, J., Xu, J., Sarma, K., Pikalov, A., & Kane, J. M.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 147
- Issue
- 1
- Pages
- 95-102
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2166033924
- Cited by
- 117
- References
- 6
- FWCI
- 8.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study. https://app.cochat.ai/papers/10.1016/j.schres.2013.03.013
- The paper
- Loebel, A., Cucchiaro, J., Xu, J., Sarma, K., Pikalov, A., & Kane, J. M. (2013). Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study. Schizophrenia Research. https://doi.org/10.1016/j.schres.2013.03.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.